CN106307547A - Lipid-lowering health piece with garlicin and preparing method thereof - Google Patents
Lipid-lowering health piece with garlicin and preparing method thereof Download PDFInfo
- Publication number
- CN106307547A CN106307547A CN201610719098.5A CN201610719098A CN106307547A CN 106307547 A CN106307547 A CN 106307547A CN 201610719098 A CN201610719098 A CN 201610719098A CN 106307547 A CN106307547 A CN 106307547A
- Authority
- CN
- China
- Prior art keywords
- garlicin
- carboxymethyl chitosan
- sheet containing
- vitamin
- bulbus allii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000036541 health Effects 0.000 title claims abstract description 26
- 238000000034 method Methods 0.000 title claims description 14
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 32
- 229920001661 Chitosan Polymers 0.000 claims abstract description 22
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims abstract description 19
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 16
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 16
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 16
- 229940046009 vitamin E Drugs 0.000 claims abstract description 16
- 239000011709 vitamin E Substances 0.000 claims abstract description 16
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 13
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 13
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 13
- 240000002234 Allium sativum Species 0.000 claims abstract description 8
- 235000004611 garlic Nutrition 0.000 claims abstract description 8
- 239000000284 extract Substances 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 241000218628 Ginkgo Species 0.000 claims description 15
- 235000011201 Ginkgo Nutrition 0.000 claims description 15
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 230000002402 anti-lipaemic effect Effects 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 238000004806 packaging method and process Methods 0.000 claims description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- 239000007779 soft material Substances 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 230000033228 biological regulation Effects 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 238000009835 boiling Methods 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 238000007689 inspection Methods 0.000 claims description 6
- 239000002002 slurry Substances 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 4
- 230000005855 radiation Effects 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000005360 mashing Methods 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 238000012856 packing Methods 0.000 claims 1
- 230000007306 turnover Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 230000007774 longterm Effects 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 230000037356 lipid metabolism Effects 0.000 abstract description 3
- 230000000295 complement effect Effects 0.000 abstract description 2
- 230000007547 defect Effects 0.000 abstract description 2
- 230000000055 hyoplipidemic effect Effects 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 239000009429 Ginkgo biloba extract Substances 0.000 abstract 2
- 229940068052 ginkgo biloba extract Drugs 0.000 abstract 2
- 235000020686 ginkgo biloba extract Nutrition 0.000 abstract 2
- 239000006000 Garlic extract Substances 0.000 abstract 1
- 235000020706 garlic extract Nutrition 0.000 abstract 1
- 239000000047 product Substances 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- XUHLIQGRKRUKPH-GCXOYZPQSA-N Alliin Natural products N[C@H](C[S@@](=O)CC=C)C(O)=O XUHLIQGRKRUKPH-GCXOYZPQSA-N 0.000 description 7
- XUHLIQGRKRUKPH-UHFFFAOYSA-N S-allyl-L-cysteine sulfoxide Natural products OC(=O)C(N)CS(=O)CC=C XUHLIQGRKRUKPH-UHFFFAOYSA-N 0.000 description 7
- XUHLIQGRKRUKPH-DYEAUMGKSA-N alliin Chemical compound OC(=O)[C@@H](N)C[S@@](=O)CC=C XUHLIQGRKRUKPH-DYEAUMGKSA-N 0.000 description 7
- 235000015295 alliin Nutrition 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 description 3
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 description 3
- 235000010081 allicin Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- IWEIJEPIYMAGTH-UHFFFAOYSA-N Bilobetin Chemical compound COC1=CC=C(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)C=C1C1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 IWEIJEPIYMAGTH-UHFFFAOYSA-N 0.000 description 2
- UBJVUCKUDDKUJF-UHFFFAOYSA-N Diallyl sulfide Chemical compound C=CCSCC=C UBJVUCKUDDKUJF-UHFFFAOYSA-N 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- MOLPUWBMSBJXER-YDGSQGCISA-N bilobalide Chemical compound O([C@H]1OC2=O)C(=O)[C@H](O)[C@@]11[C@@](C(C)(C)C)(O)C[C@H]3[C@@]21CC(=O)O3 MOLPUWBMSBJXER-YDGSQGCISA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- QWVMSYBGKWZIIE-RDFNRINOSA-N Flavochrome Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C1OC2(C)CCCC(C)(C)C2=C1)C=CC=C(/C)C=CC3C(=CCCC3(C)C)C QWVMSYBGKWZIIE-RDFNRINOSA-N 0.000 description 1
- SQGLUEWZRKIEGS-UHFFFAOYSA-N Ginkgetin Natural products C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(OC)C(C=3C(=CC=C(C=3)C=3OC4=CC(O)=CC(O)=C4C(=O)C=3)O)=C2O1 SQGLUEWZRKIEGS-UHFFFAOYSA-N 0.000 description 1
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 description 1
- 229930045534 Me ester-Cyclohexaneundecanoic acid Natural products 0.000 description 1
- 235000008575 Pinus pinea Nutrition 0.000 description 1
- 240000007789 Pinus pinea Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- QWVMSYBGKWZIIE-FZKBJVJCSA-N flavochrome Chemical compound O1C2(C)CCCC(C)(C)C2=CC1C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1C(C)=CCCC1(C)C QWVMSYBGKWZIIE-FZKBJVJCSA-N 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- AIFCFBUSLAEIBR-UHFFFAOYSA-N ginkgetin Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C(C=1)=CC=C(OC)C=1C1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 AIFCFBUSLAEIBR-UHFFFAOYSA-N 0.000 description 1
- FPUXKXIZEIDQKW-MFJLLLFKSA-N ginkgolide A Natural products O=C1[C@H](C)[C@@]2(O)[C@@H](O1)C[C@]13[C@@H]4OC(=O)[C@]21O[C@@H]1OC(=O)[C@H](O)[C@]31[C@@H](C(C)(C)C)C4 FPUXKXIZEIDQKW-MFJLLLFKSA-N 0.000 description 1
- SQOJOAFXDQDRGF-WJHVHIKBSA-N ginkgolide B Natural products O=C1[C@@H](C)[C@@]2(O)[C@@H]([C@H](O)[C@]34[C@@H]5OC(=O)[C@]23O[C@H]2OC(=O)[C@H](O)[C@@]42[C@H](C(C)(C)C)C5)O1 SQOJOAFXDQDRGF-WJHVHIKBSA-N 0.000 description 1
- FPUXKXIZEIDQKW-VKMVSBOZSA-N ginkgolide-a Chemical compound O[C@H]([C@]12[C@H](C(C)(C)C)C[C@H]3OC4=O)C(=O)O[C@H]2O[C@]24[C@@]13C[C@@H]1OC(=O)[C@@H](C)[C@]21O FPUXKXIZEIDQKW-VKMVSBOZSA-N 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- HUOOMAOYXQFIDQ-UHFFFAOYSA-N isoginkgetin Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C(C=3C(=CC=C(C=3)C=3OC4=CC(O)=CC(O)=C4C(=O)C=3)OC)=C2O1 HUOOMAOYXQFIDQ-UHFFFAOYSA-N 0.000 description 1
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 description 1
- 235000008800 isorhamnetin Nutrition 0.000 description 1
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- FDRCDNZGSXJAFP-UHFFFAOYSA-M sodium chloroacetate Chemical compound [Na+].[O-]C(=O)CCl FDRCDNZGSXJAFP-UHFFFAOYSA-M 0.000 description 1
- 229930193551 sterin Natural products 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention provides lipid-lowering health piece with garlicin, prepared from, by mass percentage, 30%-60% of garlicin, 28%-35% of ginkgo biloba extract, 10%-25% of carboxymethyl chitosan, 1%-3% of Vitamin E, and 2%-6% of maltodextrin. Garlic extract as the main raw material, with Ginkgo biloba extract, carboxymethyl chitosan, vitamin E and other hypolipidemic functional factors, developed a can improve the body's lipid metabolism of garlic compound health care products, make up the single defect for current garlic product. At the same time the synergies of various components, complementary advantages, to achieve the purpose of the best lipid-lowering. The prepared care tablets are stable with good shape, which can be used in long-term without side effects.
Description
Technical field
The present invention relates to health product and preparation method thereof field, particularly to a kind of Antilipemic health sheet containing garlicin and
Preparation method.
Background technology
In recent years, the sickness rate of the disease such as fatty liver, hyperlipidemia is in the trend risen year by year, especially in middle-aged and elderly people
Most commonly seen, seriously jeopardize quality of life and the life and health of contemporary people.In clinical treatment, Integrated TCM is mostly used to carry out
Comprehensive symptomatic treatment, clothes for patients pharmacopoeia class is many, quantity big, makes Middle Age and Aged Patients subject the long-term discomfort brought of taking medicine in a large number；
Improve, treat fatty liver, the health product the most mostly poor effect of hyperlipidemia, even affect liver metabolism, make
Become irreversible side effect, be not suitable for person in middle and old age's height fat patient's prolonged application.
Research finds, Bulbus Allii extract garlicin can remove the fat accumulated in the blood vessel, has significantly reduction
Triglycerides in Serum and the effect of total cholesterol level, can improve HDL-C simultaneously and reduce low-density
The content of lipoprotein cholesterol, and by reducing blood viscosity, the generation of suppression atherosclerotic lesion and development.
Specifically, effective ingredient allicin, allicin and multiple allyl sulphide chemical combination during it is Bulbus Allii
The general name of thing, is a kind of colorless oil with off-odor and highly volatile.That does not dissociate in fresh Bulbus Allii is big
Allicin, only its precursor substance alliin, alliin presented in stable in Bulbus Allii, when Bulbus Allii is by physics
Or after Mechanical Crushing, the oxygen molecule in air has caused the alliin together with associating with Bulbus Allii former times enzyme to resolve into garlicin.
At present, due to the shortage to Bulbus Allii process technology, Bulbus Allii be generally used to directly the most edible or cold and dressed with sauce, pickle edible,
Exploitation to Bulbus Allii deep processing health promoting product is the most limited, how the pharmacological action of Bulbus Allii is brought into play and makes one and can change
Kind human metabolism function, the health product of lowering fat and protecting liver have become a new difficult problem.
Summary of the invention
The main object of the present invention is in order to make up the problems referred to above, it is provided that one can be improved human body blood lipid metabolism comprehensively, adjust blood
The Antilipemic health sheet containing garlicin of pressure drop blood fat.
The present invention proposes a kind of Antilipemic health sheet containing garlicin, calculates according to mass percent, and it includes 30%-60%
Garlicin, the Folium Ginkgo extract of 28%-35%, the carboxymethyl chitosan of 10%-25%, 1%-3% vitamin E, 2%-
The maltodextrin of 6%.
Preferably, calculate according to mass percent, garlicin including 50%, the Folium Ginkgo extract of 35%, 10%
Carboxymethyl chitosan, 2% vitamin E and the maltodextrin of 3%.
The present invention also proposes the preparation method of a kind of Antilipemic health sheet containing garlicin, comprises the steps:
S10, according to setting ratio weigh the garlicin through quality inspection, Folium Ginkgo extract, carboxymethyl chitosan and
Vitamin E, is placed in mixer and mixes 20 30min；
S20, weighs the maltodextrin set in proportion, dilutes with boiling water with after a small amount of cold water suspendible again, and stirring is all
Even formation concentration be 10% mixing slurry after join in the mixture of step S10, make mixture be bonded together, soft to make
Material；
S30, the soft material after the process of step S20 being completed is placed in oscillating granulator makes wet granular, then by week
Turn case and proceed in drying room, be dried when being less than 5% to moisture content and proceed to rotary tablet machine is carried out tabletting, finally load packaging
In tank or packaging bag.
Preferably, described in step S10, garlicin is prepared via a method which:
S11, pretreatment: take fresh garlic, peeling is pounded mashed garlic with tissue mashing machine after cleaning, and adds deionized water stirring all
With 200w microwave radiation 2 5min after even, obtain Bulbus Allii serosity；
S12, enzymolysis: be 45 to be placed on 30 45 DEG C of water-baths with hydrochloric acid that concentration is 15% regulation Bulbus Allii plasm PH value
Middle enzymolysis 0.5 2h postlyophilization 6h, obtains treatment fluid；
S13, extraction: adding volume fraction in treatment fluid is that the ethanol of 90% extracts 0.8 1.2h at 30 50 DEG C,
After 3500r/min is centrifuged 10 15min, take supernatant liquid filtering；Wherein the quality for the treatment of fluid is 1g:5mL with the ratio of ethanol volume；
S14, concentrating under reduced pressure: the supernatant after filtration is 50 DEG C in temperature, pressure 0.01MPa, the condition of rotating speed 75r/min
Under, carry out concentrating under reduced pressure with Rotary Evaporators, obtain the garlicin concentrated.
Preferably, in step S12, Bulbus Allii serosity is placed on enzymolysis 0.5h in 40 DEG C of water-baths through hydrochloric acid regulation pH value.
The present invention with Bulbus Allii extract as primary raw material, compatibility Folium Ginkgo extract, carboxymethyl chitosan, vitamin E etc.
The hypolipemic function factor, develops a kind of garlicin complex health care product that can improve human body blood lipid metabolism, compensate for current Bulbus Allii
The defect that element product function is single.The most each component Synergistic, has complementary advantages, reaches the purpose of optimal blood fat reducing.System of the present invention
Standby health care tablet is stable, good moldability, long-term use without side effects.This product meets becoming of health care of food development in the world
Gesture, has the good prospect of marketing.
Detailed description of the invention
Should be appreciated that specific embodiment described herein, only in order to explain the present invention, is not intended to limit the present invention
Scope.
The present invention proposes a kind of Antilipemic health sheet containing garlicin, calculates according to mass percent, and it includes 30%-60%
Garlicin, the Folium Ginkgo extract of 28%-35%, the carboxymethyl chitosan of 10%-25%, 1%-3% vitamin E, 2%-
The maltodextrin of 6%.
Preferably, calculate according to mass percent, garlicin including 50%, the Folium Ginkgo extract of 35%, 10%
Carboxymethyl chitosan, 2% vitamin E and the maltodextrin of 3%.
The effective ingredient of Folium Ginkgo extract mainly includes that flavonoid glycoside is (containing single ketones such as campherol, isorhamnetin, flavochrome
The bis-flavonoids such as compounds and arnentoflavone, bilobetin, ginkgetin, 4',4'''-Dimethylamentoflavone., parasol pine flavin) and
Terpenoid (includes Ginkgolide A. B. C, J and bilobalide).These compositions have obviously pharmacological effect, and it can expand blood
Pipe, strengthens blood circulation, to free radical resisting, effectively prevents thrombosis, regulation blood fat from reducing blood pressure.There is reduction serum gallbladder simultaneously
Sterin, the effect of coronary artery dilator.
Chitosan major function is regulation human immune system, improves resistance against diseases.It can effectively resist the rising of TC, right
HDL-Ch has rising effect, the most edible rising that can prevent serum cholesterol, plays a role gerocomia.But, shell
The existence of hydrogen bond between glycan molecule, makes it cannot be soluble in water.It need to be carried out structural modification, make soluble derivative carboxylic
Methyl chitosan, widens its range of application.Carboxymethyl chitosan good water solubility, toughness, it is difficult to the moisture absorption, is to prepare Antilipemic health
The preferable adjuvant of sheet.
Further, in practical operation, the preparation method of carboxymethyl chitosan is as follows: by refined chitosan, first use
Mass concentration is that 50% sodium hydroxide is basified, then the mixed liquor dripping monoxone and isopropanol reacts, and is adjusted to neutrality, then
With mass concentration be 80% methanol washing, the white product of gained is carboxymethyl chitosan.Then by this white product
Pulverize standby.
Vitamin E has the strongest antioxidation, can prevent fatty compound, delays cell aging because of oxidation.Promote
Blood circulation, reduces cholesterol, prevention of stroke.
Maltodextrin has good emulsification and thickening power, promotes formed product and good suppression product knot of tissue
Structure effect；Filming performance is good, can prevent deformation of products, can improve again product appearance；The most digested, the suitableeest
Preferably make the basic material of health food.
Specifically, the present invention is had the health-care tablet containing garlicin of effect for reducing fat and is made by following method:
S10, according to setting ratio weigh the garlicin through quality inspection, Folium Ginkgo extract, carboxymethyl chitosan and
Vitamin E, is placed in mixer and mixes 20 30min；
S20, weighs the maltodextrin set in proportion, dilutes with boiling water with after a small amount of cold water suspendible again, and stirring is all
Even formation concentration be 10% mixing slurry after join in the mixture of step S10, make mixture be bonded together, soft to make
Material；
S30, the soft material after the process of step S20 being completed is placed in oscillating granulator makes wet granular, then by week
Turn case and proceed in drying room, be dried when being less than 5% to moisture content and proceed to rotary tablet machine is carried out tabletting, finally load packaging
In tank or packaging bag.
Further, described in step S10, garlicin is prepared via a method which:
S11, pretreatment: take fresh garlic, peeling is pounded mashed garlic with tissue mashing machine after cleaning, and adds deionized water stirring all
With 200w microwave radiation 2 5min after even, obtain Bulbus Allii serosity；
Utilize the heat effect that microwave radiation produces inside the vascular tissue of Bulbus Allii so that it is in vascular bundle and glandular cell's system
Heat up faster, and this temperature can be kept until its internal pressure exceedes the ability of cell wall expansion, cause cell rupture, thus
Make to be positioned at intracellular alliin to flow out, transmit and transfer to, the serosity of surrounding, to facilitate follow-up enzymolysis step from cell wall.
S12, enzymolysis: be 45 to be placed on 30 45 DEG C of water-baths with hydrochloric acid that concentration is 15% regulation Bulbus Allii plasm PH value
Middle enzymolysis 0.5 2h postlyophilization 6h, obtains treatment fluid；
The step of enzymolysis is to promote alliin to convert to garlicin.Preferably, 40 DEG C of water-baths are placed 0.5h.Enzymolysis
Temperature is the lowest, and the activity of allinase is little, and the time that catalysis alliin is converted into garlicin is oversize；And temperature is the highest, the Bulbus Allii of generation
Element is easy to again decompose.Enzymolysis time is the shortest, and alliin can not be sufficiently converted into garlicin and enzymolysis；And enzymolysis time is long,
Garlicin is readily volatilized or is converted into by-product, affects yield and quality.Thus when temperature is 40 DEG C, and enzymolysis time is 0.5h
Time, the yield of garlicin is the highest.
The yield of the garlicin of freeze-dried process is greatly improved, and main cause is that lyophilization can greatly reduce greatly
The moisture of Bulbus Allii sample, follow-up extraction.
S13, extraction: adding volume fraction in treatment fluid is that the ethanol of 90% extracts 0.8 1.2h at 30 50 DEG C,
After 3500r/min is centrifuged 10 15min, take supernatant liquid filtering；Wherein the quality for the treatment of fluid is 1g:5mL with the ratio of ethanol volume；
Time centrifugal, rotating speed was advisable with 10 15min with 3500r/min, time.If speed is the slowest, can make centrifugal the most thorough；
Garlicin can be caused time too fast to dissolve insufficient.
S14, concentrating under reduced pressure: the supernatant after filtration is 50 DEG C in temperature, pressure 0.01MPa, the condition of rotating speed 75r/min
Under, carry out concentrating under reduced pressure with Rotary Evaporators, obtain the garlicin concentrated.
This step is used for removing lixiviating solution ethanol.
Embodiment 1:
S10, weigh the garlicin 300g through quality inspection, Folium Ginkgo extract 280g, carboxymethyl chitosan 150g and
Vitamin E 10g, is placed in mixer mixing 30min；
S20, weighs maltodextrin 60g, dilutes with boiling water with after a small amount of cold water suspendible again, and the formation concentration that stirs is
Join after the mixing slurry of 10% in the mixture of step S10, make mixture be bonded together, to make soft material；
S30, the soft material after the process of step S20 being completed is placed in oscillating granulator makes wet granular, then by week
Turn case and proceed in drying room, be dried when being less than 5% to moisture content and proceed to rotary tablet machine is carried out tabletting, finally load packaging
In tank or packaging bag.
Embodiment 2:
S10, weigh the garlicin 500g through quality inspection, Folium Ginkgo extract 350g, carboxymethyl chitosan 100g and
Vitamin E 20g, is placed in mixer mixing 20min；
S20, weighs maltodextrin 30g, dilutes with boiling water with after a small amount of cold water suspendible again, and the formation concentration that stirs is
Join after the mixing slurry of 10% in the mixture of step S10, make mixture be bonded together, to make soft material；
S30, the soft material after the process of step S20 being completed is placed in oscillating granulator makes wet granular, then by week
Turn case and proceed in drying room, be dried when being less than 5% to moisture content and proceed to rotary tablet machine is carried out tabletting, finally load packaging
In tank or packaging bag.
Embodiment 3:
S10, weigh the garlicin 600g through quality inspection, Folium Ginkgo extract 300g, carboxymethyl chitosan 250g and
Vitamin E 30g, is placed in mixer mixing 20min；
S20, weighs maltodextrin 20g, dilutes with boiling water with after a small amount of cold water suspendible again, and the formation concentration that stirs is
Join after the mixing slurry of 10% in the mixture of step S10, make mixture be bonded together, to make soft material；
S30, the soft material after the process of step S20 being completed is placed in oscillating granulator makes wet granular, then by week
Turn case and proceed in drying room, be dried when being less than 5% to moisture content and proceed to rotary tablet machine is carried out tabletting, finally load packaging
In tank or packaging bag.
Now the Antilipemic health sheet containing garlicin prepared by case study on implementation 13 of the present invention is tested:
Object and method: hyperlipidemia patient 60 example, be divided into 3 groups, often organizes male 10 examples, female 10 example.42 78 years old age, averagely
56.2 years old, disable other fat reducing health products, singly take this product, 1 day 1 time, each 5g, takes continuously 6 weeks, measures before self taking
After serum cholesterol (TC), triglyceride (TG), the change of HDL-C (HDL-Ch).(data are average
Value)
Take before and after hyperlipemia Parameters variation (cB/mmol-1)
Observed result: taken the change of before and after's own control lipid parameter, 60 example hyperlipemia serum from above-mentioned
TC, serum TG are substantially reduced, and Serum HDL-C h level is effectively raised, and take period patient without any untoward reaction.
From above-mentioned data: the Antilipemic health sheet containing garlicin prepared by the present invention is extracted by garlicin, Folium Ginkgo
The characteristic of thing, vitamin E and carboxymethyl chitosan and Synergistic, improve significantly to the hyperlipidemia of human body, long-term taking
Have no side effect.
The foregoing is only presently preferred embodiments of the present invention, not in order to limit the present invention, all spirit in the present invention and
Within principle, any modification, equivalent substitution and improvement etc. made, should be included within the scope of the present invention.
Claims (5)
1. the Antilipemic health sheet containing garlicin, it is characterised in that calculate according to mass percent, including 30%-60%'s
Garlicin, the Folium Ginkgo extract of 28%-35%, the carboxymethyl chitosan of 10%-25%, 1%-3% vitamin E, 2%-6%
Maltodextrin.
2. the Antilipemic health sheet containing garlicin as claimed in claim 1, it is characterised in that calculate according to mass percent, bag
The Fructus Hordei Germinatus of the garlicin, the Folium Ginkgo extract of 35%, the carboxymethyl chitosan of 10%, 2% vitamin E and 3% that include 50% is stuck with paste
Essence.
3. the preparation method of the Antilipemic health sheet containing garlicin, it is characterised in that comprise the steps:
S10, weighs the garlicin through quality inspection, Folium Ginkgo extract, carboxymethyl chitosan and dimension according to setting ratio raw
Element E, is placed in mixer and mixes 20 30min；
S20, weighs the maltodextrin set in proportion, dilutes with boiling water with after cold water suspendible again, and the formation that stirs is dense
Degree be 10% mixing slurry after join in the mixture of step S10, make mixture be bonded together, to make soft material；
S30, the soft material after the process of step S20 being completed is placed in oscillating granulator makes wet granular, then passes through Turnover Box
Proceed in drying room, be dried to moisture content less than 5% time proceed to rotary tablet machine is carried out tabletting, finally load packing jar or
In packaging bag.
4. the preparation method of the Antilipemic health sheet containing garlicin as claimed in claim 3, it is characterised in that institute in step S10
State garlicin to be prepared via a method which:
S11, pretreatment: take fresh garlic, peeling is pounded mashed garlic with tissue mashing machine after cleaning, and adds after deionized water stirs
With 200w microwave radiation 2 5min, obtain Bulbus Allii serosity；
S12, enzymolysis: be 45 to be placed on enzyme in 30 45 DEG C of water-baths with hydrochloric acid that concentration is 15% regulation Bulbus Allii plasm PH value
Solve 0.5 2h postlyophilization 6h, obtain treatment fluid；
S13, extraction: adding volume fraction in treatment fluid is that the ethanol of 90% extracts 0.8 1.2h at 30 50 DEG C,
After 3500r/min is centrifuged 10 15min, take supernatant liquid filtering；Wherein the quality for the treatment of fluid is 1g:5mL with the ratio of ethanol volume；
S14, concentrating under reduced pressure: the supernatant after filtration is 50 DEG C in temperature, pressure 0.01MPa, under conditions of rotating speed 75r/min,
Carry out concentrating under reduced pressure with Rotary Evaporators, obtain the garlicin extracted.
5. the preparation method of the Antilipemic health sheet containing garlicin as claimed in claim 4, it is characterised in that in step S12, greatly
Bulbus Allii serosity is placed on enzymolysis 0.5h in 40 DEG C of water-baths through hydrochloric acid regulation pH value.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610719098.5A CN106307547A (en) | 2016-08-24 | 2016-08-24 | Lipid-lowering health piece with garlicin and preparing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610719098.5A CN106307547A (en) | 2016-08-24 | 2016-08-24 | Lipid-lowering health piece with garlicin and preparing method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106307547A true CN106307547A (en) | 2017-01-11 |
Family
ID=57791346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610719098.5A Withdrawn CN106307547A (en) | 2016-08-24 | 2016-08-24 | Lipid-lowering health piece with garlicin and preparing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106307547A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107296799A (en) * | 2017-07-05 | 2017-10-27 | 北京罗麦科技有限公司 | A kind of allicin tablet and preparation method thereof |
| CN107594534A (en) * | 2017-10-20 | 2018-01-19 | 广州润虹医药科技股份有限公司 | A kind of compound nutrient liquor with effects of losing weight and lowering blood sugar and blood lipid and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101455180A (en) * | 2009-01-09 | 2009-06-17 | 华中科技大学 | Open type plant tissue culture seedlings-raising method |
| CN101780181A (en) * | 2009-01-16 | 2010-07-21 | 陈祥槐 | Nitric oxide free radical health care product |
| CN102743458A (en) * | 2011-11-28 | 2012-10-24 | 宁波海逸生物科技有限公司 | Formula of health drug with effects blood fat regulating and immunity increasing |
| CN103330119A (en) * | 2013-06-07 | 2013-10-02 | 青岛银龄美海洋生物科技有限公司 | Health-care food for accessorily reducing blood fat |
| CN104013050A (en) * | 2014-06-18 | 2014-09-03 | 南京麦思德餐饮管理有限公司 | Alliaceous sports beverage |
| CN104208270A (en) * | 2013-06-03 | 2014-12-17 | 谢金魁 | Radiation resistant lozenge |
-
2016
- 2016-08-24 CN CN201610719098.5A patent/CN106307547A/en not_active Withdrawn
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101455180A (en) * | 2009-01-09 | 2009-06-17 | 华中科技大学 | Open type plant tissue culture seedlings-raising method |
| CN101780181A (en) * | 2009-01-16 | 2010-07-21 | 陈祥槐 | Nitric oxide free radical health care product |
| CN102743458A (en) * | 2011-11-28 | 2012-10-24 | 宁波海逸生物科技有限公司 | Formula of health drug with effects blood fat regulating and immunity increasing |
| CN104208270A (en) * | 2013-06-03 | 2014-12-17 | 谢金魁 | Radiation resistant lozenge |
| CN103330119A (en) * | 2013-06-07 | 2013-10-02 | 青岛银龄美海洋生物科技有限公司 | Health-care food for accessorily reducing blood fat |
| CN104013050A (en) * | 2014-06-18 | 2014-09-03 | 南京麦思德餐饮管理有限公司 | Alliaceous sports beverage |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107296799A (en) * | 2017-07-05 | 2017-10-27 | 北京罗麦科技有限公司 | A kind of allicin tablet and preparation method thereof |
| CN107594534A (en) * | 2017-10-20 | 2018-01-19 | 广州润虹医药科技股份有限公司 | A kind of compound nutrient liquor with effects of losing weight and lowering blood sugar and blood lipid and preparation method thereof |
| CN107594534B (en) * | 2017-10-20 | 2020-09-15 | 广州润虹医药科技股份有限公司 | Compound nutrient solution with functions of losing weight, reducing blood sugar and reducing blood fat and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102613649B (en) | Semi-skimmed trichosanthes kirilowii maxim protein beverage and preparation method thereof | |
| CN106819750A (en) | Hypoglycemic solid beverage of a kind of aided blood pressure-lowering and preparation method thereof | |
| CN103960568B (en) | A kind of general ginsenoside chewable tablets and preparation method thereof | |
| CN104544090B (en) | A kind of preparation method of instant Semen Ginkgo | |
| CN103211866A (en) | Soft capsule used for improving body immunity and heart and cerebral vessel function | |
| CN108522994A (en) | Radix Astragali oat rice flour | |
| CN106307547A (en) | Lipid-lowering health piece with garlicin and preparing method thereof | |
| CN106723089A (en) | The method of insoluble diedairy fiber in high efficiency extraction sweet potato waste | |
| CN105961633A (en) | Peony seed oil blended oil and manufacturing method thereof | |
| CN103690819A (en) | Traditional Chinese medicinal composition capable of preventing and treating cardiovascular and cerebrovascular diseases and with weight reducing function | |
| CN105831733A (en) | Tea oil lipid reducing capsule | |
| CN105950284A (en) | Health peanut oil and preparation method thereof | |
| CN104288566B (en) | Traditional Chinese medicine composition for reducing cholesterol and/or reducing blood lipids as well as preparation method and application of traditional Chinese medicine composition | |
| CN109112031A (en) | A kind of honey health preserving wine and preparation method thereof | |
| CN103535734A (en) | Drug bag for improving sleep and preparation method thereof | |
| CN103704703B (en) | A kind of Chinese yam-Chinese date dispersing tablet and preparation method | |
| CN106720829A (en) | A kind of polygonatum Solomon's seal sugar-tablet and preparation method thereof | |
| CN102511711A (en) | Healthcare food capsule and preparation method for same | |
| CN101869298A (en) | Compound walnut and linseed oil fat emulsion oral solution, beverage and preparation method | |
| CN105995996A (en) | Preparation method of oral liquid for preventing constipation in pregnancy | |
| CN102715508B (en) | Compound walnut soft shell capsule enhanced nourishment | |
| CN109430847A (en) | A kind of tea oil soft capsule and preparation method thereof | |
| CN105942518A (en) | Health-caring composition containing peony seed oil and preparation method thereof | |
| CN105076442A (en) | Blueberry milk tablet and preparation method thereof | |
| CN109042907A (en) | A kind of preparation method of corn oil |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170111 |